Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Leap Therapeutics, Inc. (LPTX : NSDQ)
 
 • Company Description   
Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States.

Number of Employees: 30

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.39 Daily Weekly Monthly
20 Day Moving Average: 1,709,580 shares
Shares Outstanding: 88.32 (millions)
Market Capitalization: $211.08 (millions)
Beta: 0.32
52 Week High: $4.17
52 Week Low: $1.33
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.15% -7.35%
12 Week 59.33% 57.75%
Year To Date 6.22% -8.09%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
47 THORNDIKE STREET SUITE B1-1
-
CAMBRIDGE,MA 02141
USA
ph: 617-714-0360
fax: -
leap@argotpartners.com http://www.leaptx.com
 
 • General Corporate Information   
Officers
Douglas E. Onsi - Chief Executive Officer; President and Chief Finan
Christopher K. Mirabelli - Chairman
Monica M. Bertagnolli - Director
James Cavanaugh - Director
Thomas Dietz - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 52187K101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 03/11/22
Share - Related Items
Shares Outstanding: 88.32
Most Recent Split Date: (:1)
Beta: 0.32
Market Capitalization: $211.08 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.49 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.81
Price/Cash Flow: -
Price / Sales: 140.72
EPS Growth
vs. Year Ago Period: -55.56%
vs. Previous Quarter: -16.67%
Sales Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 0.00%
ROE
09/30/21 - -63.02
06/30/21 - -77.18
03/31/21 - -59.46
ROA
09/30/21 - -54.86
06/30/21 - -65.29
03/31/21 - -51.52
Current Ratio
09/30/21 - 11.11
06/30/21 - 4.47
03/31/21 - 5.92
Quick Ratio
09/30/21 - 11.11
06/30/21 - 4.47
03/31/21 - 5.92
Operating Margin
09/30/21 - -2,433.93
06/30/21 - -2,161.80
03/31/21 - -1,961.13
Net Margin
09/30/21 - -2,433.93
06/30/21 - -2,161.80
03/31/21 - -1,961.13
Pre-Tax Margin
09/30/21 - -2,434.07
06/30/21 - -2,161.93
03/31/21 - -1,961.27
Book Value
09/30/21 - 1.32
06/30/21 - 0.50
03/31/21 - 0.64
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - 0.00
Debt-to-Capital
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - 0.00
 

Powered by Zacks Investment Research ©